Sunshine Biopharma Inc. Depreciation
Sunshine Biopharma Inc. (SBFM) reported Depreciation of $176.35 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-04-03
- Sunshine Biopharma Inc. depreciation for the quarter ending 2025-12-31 was -$56.80K.
- Sunshine Biopharma Inc. depreciation for the quarter ending 2025-09-30 was $95.82K, a 48.27% increase year-over-year.
- Sunshine Biopharma Inc. depreciation for the quarter ending 2025-06-30 was $72.53K, a 42.59% increase year-over-year.
- Sunshine Biopharma Inc. depreciation for the quarter ending 2025-03-31 was $64.79K, a 52.03% increase year-over-year.
- Sunshine Biopharma Inc. depreciation for fiscal 2025 was $176.35K, a 20.36% increase from fiscal 2024.
- Sunshine Biopharma Inc. depreciation for fiscal 2024 was $146.52K, a 32.35% increase from fiscal 2023.
- Sunshine Biopharma Inc. depreciation for fiscal 2023 was $110.70K, a 436.32% increase from fiscal 2022.
- Sunshine Biopharma Inc. depreciation for fiscal 2022 was $20.64K, a 62.00% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$56.80K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $39.02K derived: sum of 2 quarters · filed 2026-04-03 | $111.55K derived: sum of 3 quarters · filed 2026-04-03 | $176.35K 10-K · filed 2026-04-03 |
| 2025-09-30 | $95.82K 10-Q · filed 2025-11-13 | $168.35K derived: sum of 2 quarters · filed 2025-11-13 | $233.15K 10-Q · filed 2025-11-13 | $221.55K derived: sum of 4 quarters · filed 2026-04-03 |
| 2025-06-30 | $72.53K 10-Q · filed 2025-08-12 | $137.33K 10-Q · filed 2025-08-12 | $125.73K derived: sum of 3 quarters · filed 2026-04-03 | $190.36K derived: sum of 4 quarters · filed 2026-04-03 |
| 2025-03-31 | $64.79K 10-Q · filed 2025-05-15 | $53.20K derived: sum of 2 quarters · filed 2026-04-03 | $117.82K derived: sum of 3 quarters · filed 2026-04-03 | $168.69K derived: sum of 4 quarters · filed 2026-04-03 |
| 2024-12-31 | -$11.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $53.03K derived: sum of 2 quarters · filed 2026-04-03 | $103.90K derived: sum of 3 quarters · filed 2026-04-03 | $146.52K 10-K · filed 2026-04-03 |
| 2024-09-30 | $64.63K 10-Q · filed 2025-11-13 | $115.50K derived: sum of 2 quarters · filed 2025-11-13 | $158.12K 10-Q · filed 2025-11-13 | $162.02K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $50.87K 10-Q · filed 2025-08-12 | $93.49K 10-Q · filed 2025-08-12 | $97.39K derived: sum of 3 quarters · filed 2025-08-12 | $134.60K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $42.62K 10-Q · filed 2025-05-15 | $46.52K derived: sum of 2 quarters · filed 2025-05-15 | $83.73K derived: sum of 3 quarters · filed 2025-05-15 | $118.61K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.90K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $41.11K derived: sum of 2 quarters · filed 2025-04-01 | $75.99K derived: sum of 3 quarters · filed 2025-04-01 | $110.70K 10-K · filed 2025-04-01 |
| 2023-09-30 | $37.21K 10-Q · filed 2024-11-05 | $72.09K derived: sum of 2 quarters · filed 2024-11-05 | $106.80K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $34.88K 10-Q/A · filed 2024-08-20 | $69.59K 10-Q/A · filed 2024-08-20 | ||
| 2022-12-31 | $14.46K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $15.24K derived: sum of 2 quarters · filed 2024-03-28 | $17.53K derived: sum of 3 quarters · filed 2024-03-28 | $20.64K 10-K · filed 2024-03-28 |
| 2022-09-30 | $789.00 10-Q · filed 2023-11-13 | $3.08K derived: sum of 2 quarters · filed 2023-11-13 | $6.19K 10-Q · filed 2023-11-13 | $9.37K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.29K 10-Q · filed 2023-08-10 | $5.40K 10-Q · filed 2023-08-10 | $8.58K derived: sum of 3 quarters · filed 2023-08-10 | $11.76K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.11K 10-Q · filed 2022-05-06 | $6.29K derived: sum of 2 quarters · filed 2022-05-06 | $9.48K derived: sum of 3 quarters · filed 2022-11-07 | $12.67K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-12-31 | $3.18K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $6.37K derived: sum of 2 quarters · filed 2022-11-07 | $9.56K derived: sum of 3 quarters · filed 2022-11-07 | $12.74K 10-K · filed 2022-03-21 |
| 2021-09-30 | $3.18K 10-Q · filed 2022-11-07 | $6.38K derived: sum of 2 quarters · filed 2022-11-07 | $9.56K 10-Q · filed 2022-11-07 | $13.10K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $3.19K 10-Q · filed 2022-08-03 | $6.37K 10-Q · filed 2022-08-03 | $9.91K derived: sum of 3 quarters · filed 2022-08-03 | $13.44K derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $3.18K 10-Q · filed 2022-05-06 | $6.72K derived: sum of 2 quarters · filed 2022-05-06 | $10.25K derived: sum of 3 quarters · filed 2022-05-06 | $13.74K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $3.54K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $7.06K derived: sum of 2 quarters · filed 2022-03-21 | $10.55K derived: sum of 3 quarters · filed 2022-03-21 | $14.07K 10-K · filed 2022-03-21 |
| 2020-09-30 | $3.52K 10-Q · filed 2021-11-09 | $7.01K derived: sum of 2 quarters · filed 2021-11-09 | $10.53K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $3.49K 10-Q · filed 2021-08-09 | $7.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $3.51K 10-Q · filed 2021-05-11 | |||
| 2019-09-30 | $3.47K 10-Q · filed 2020-11-12 | $6.89K derived: sum of 2 quarters · filed 2020-11-12 | $10.30K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $3.42K 10-Q/A · filed 2020-08-31 | $6.83K 10-Q/A · filed 2020-08-31 | ||
| 2019-03-31 | $3.41K 10-Q · filed 2020-05-18 | |||
| 2016-12-31 | $1.81K 10-K · filed 2017-04-17 | |||
| 2015-12-31 | $479.00 10-K · filed 2017-04-17 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |